The need for combination drug therapies in patients with complex dyslipidemia

Area of Science:

• Cardiology
• Pharmacology
• Genetics

Background:

• Statins are primary treatment for cardiovascular disease (CVD) prevention.
• Many high-risk patients fail to achieve target low-density lipoprotein cholesterol (LDL-C) levels with statins alone.
• Specific conditions like familial hypercholesterolemia and metabolic syndrome contribute to hyperlipidemia and residual CVD risk.

Purpose of the Study:

• To review the efficacy of additional lipid-lowering therapies when combined with statins.
• To assess the role of newer agents in managing patients with complex dyslipidemias and residual CVD risk.
• To evaluate the evidence for CVD outcome benefits of add-on therapies to statins.

Main Methods:

• Literature review of clinical trials and studies on lipid-lowering therapies.
• Analysis of data regarding patient populations with hyperlipidemia, including those with genetic disorders or secondary causes.
• Examination of evidence for cardiovascular outcomes and lipid profile improvements with various add-on treatments.

Main Results:

• Ezetimibe has demonstrated CVD outcome benefits in patients with chronic kidney disease.
• Combination therapies with omega-3 fatty acids, fibrates, or niacin have shown limited benefits, with a potential exception for fibrates in diabetic patients with specific lipid profiles.
• Novel agents like PCSK9 inhibitors, mipomersen, lomitapide, and CETPIs show promise for lipid profile modification, though hard outcome data is pending for some.
• Two cholesterol ester transfer protein inhibitors (CETPIs) failed to show benefit in outcome trials.

Conclusions:

• While statins are foundational, many patients require additional therapies to manage dyslipidemia and reduce residual cardiovascular risk.
• Ezetimibe and certain novel agents show potential for improving lipid profiles and potentially CVD outcomes in specific patient groups.
• The overall benefit of adding therapies to statins for CVD prevention remains uncertain for the general high-risk population but may be beneficial in complex dyslipidemias.